On this page
Quick Reference
Overview and Recommendations
Background
- •Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit that affects approximately 85% of individuals aged 12-24 years, making it the most common skin condition in this age group. Beyond its physical manifestations, acne carries significant psychosocial burden, including depression, anxiety, and body dysmorphic disorder, and can lead to permanent atrophic scarring if untreated.
- •The pathogenesis rests on four interdependent pillars: follicular hyperkeratinization (abnormal desquamation of follicular keratinocytes), increased sebum production driven by androgens, colonization by Cutibacterium acnes, and a complex inflammatory cascade that involves both innate and adaptive immunity. Each pillar represents a potential therapeutic target.
- •Acne is classified by lesion type (comedonal, papulopustular, nodular, conglobate) and severity (mild, moderate, severe, very severe). The European four-point scale and the FDA Investigator Global Assessment (IGA) are the most commonly used grading systems, linking severity to treatment escalation.
- •Major modifiable risk factors include a high-glycemic diet, dairy consumption, and psychological stress. Genetic predisposition is substantial: homozygosity for the 192-bp allele of the IGF-1 gene promoter confers a 4.29-fold increased odds of developing acne and a 3.08-fold odds of higher severity.
- •Untreated moderate-to-severe acne carries a high risk of permanent scarring, atrophic, hypertrophic, or keloidal, and postinflammatory hyperpigmentation, particularly in skin of color. The psychological impact is profound: a 2020 meta-analysis reported a significant association with depression (r=0.22) and anxiety (r=0.25).
- •The paradigm of acne management has shifted from a sequential trial of therapies to a severity-stratified, proactive approach emphasizing early use of combination therapy and maintenance to prevent relapse and scarring. Isotretinoin remains the gold standard for severe disease, but laser and photodynamic therapies offer emerging alternatives.
Evaluation
- •Suspect acne vulgaris in any patient presenting with comedones (open blackheads and closed whiteheads), inflammatory papules, pustules, or nodules distributed across the face, chest, and back, typically in an adolescent or young adult. The presence of comedones is a diagnostic hallmark that distinguishes acne from rosacea or folliculitis.
- •Ask about the age of onset, duration, menstrual cycle exacerbations in females, prior treatments (including over-the-counter products), family history of acne, and use of comedogenic cosmetics, hair products, or medications such as corticosteroids, lithium, or anabolic steroids.
- •Examine the skin in a well-lit room; count the number of inflammatory and non-inflammatory lesions on the face, chest, and back. Document the predominant lesion type and severity using a standardized scale such as the IGA or European four-point classification.
- •In women with signs of hyperandrogenism (hirsutism, alopecia, irregular menses, clitoromegaly), order an endocrine workup including free testosterone, DHEA-S, LH/FSH, and consider screening for polycystic ovary syndrome (PCOS).
- •Diagnosis is clinical; no laboratory or histopathologic testing is required for typical cases. Biopsy is reserved for atypical presentations such as unilateral distribution, perioral involvement, or absence of comedones, to rule out rosacea, folliculitis, or cutaneous lymphoma.
- •Consider standardized skin surface biopsy (SSSB) if Demodex mite infestation is suspected, as Demodex is significantly more common in acne patients (p=0.001) and may require specific treatment.
- •Grade severity using the European four-point scale: Grade 1 (comedonal acne), Grade 2 (mild-moderate papulopustular), Grade 3 (severe papulopustular or moderate nodular), Grade 4 (severe nodular or conglobate). This classification directly guides treatment selection.
- •Use the FDA Investigator Global Assessment (IGA) for clinical trials and standardized documentation. Lesion counts provide objective metrics but do not capture lesion size, visibility, or patient distress, which are important for treatment decisions.
- •Screen for psychological comorbidity using validated tools such as the PHQ-9 for depression and GAD-7 for anxiety. A 2020 meta-analysis found significant associations with both depression (r=0.22) and anxiety (r=0.25), warranting low-threshold referral to mental health services.
- •In preadolescent children (age 2-7) presenting with acne, assess for signs of early puberty: obtain a hand X-ray for bone age and refer to endocrinology if bone age is advanced or there are other signs of precocious puberty.
- •Identify risk factors for relapse: severe seborrhea, young age at onset, family history of acne, prepubertal onset, truncal involvement, and prolonged antibiotic use (>12 weeks). These factors independently predict poorer outcomes.
- •Also consider: if a patient presents with sudden-onset severe acne in adulthood, especially in a woman with no prior history, consider an endocrine workup for hyperandrogenism and rule out androgen-secreting tumors.
Management
- •Initiate treatment based on severity: for mild comedonal acne, start a topical retinoid such as adapalene 0.1% gel once daily at bedtime, or tretinoin 0.025% cream. Apply a pea-sized amount to the entire face, avoiding the eyes and mucous membranes.
- •For mild to moderate papulopustular acne, use a fixed-dose combination of adapalene 0.1%/benzoyl peroxide 2.5% gel once daily. This combination provides superior efficacy to either agent alone and is well-tolerated.
- •Alternatively, use clindamycin 1%/benzoyl peroxide 5% gel twice daily, but limit the antibiotic component to 3 months to minimize the risk of C. acnes resistance. Always combine with a non-antibiotic topical agent.
- •For moderate to severe inflammatory acne, add an oral antibiotic: doxycycline 100 mg twice daily or minocycline 100 mg twice daily for 8-12 weeks. Do not use oral antibiotics as monotherapy; always combine with a topical retinoid and/or benzoyl peroxide.
- •For severe nodular or conglobate acne, initiate isotretinoin at 0.5-1.0 mg/kg/day in two divided doses, targeting a cumulative dose of 120-150 mg/kg. Monitor for cheilitis, dry skin, myalgias, elevated triglycerides, and transaminitis at baseline and monthly.
- •In women of childbearing potential, isotretinoin requires two forms of contraception, monthly pregnancy tests, and enrollment in the iPledge program due to teratogenicity. Treatment must be initiated on the second day of the menstrual cycle.
- •For maintenance therapy after acute control, continue adapalene/BPO or BPO alone once daily for at least 24 weeks. This reduces the relapse rate from to 10.8% (NNT ≈ 3) and prevents progression of atrophic scarring.
- •For patients unable to tolerate oral antibiotics or isotretinoin, consider modified photodynamic therapy (M-PDT) with 3-5% ALA, 30-minute incubation, red light at 630 nm and 150 J/cm², delivered up to 5 weekly sessions. Onset of improvement is within 1 week.
- •Laser therapy options: pulsed dye laser (595 nm) reduces inflammatory lesions by up to 82.5%; the 1726 nm diode laser targets sebaceous glands and reduces inflammatory lesions by 56% with 3 sessions. Dual-wavelength 589/1319 nm laser is effective as an adjunct to BPO.
- •For large, painful nodules, inject intralesional triamcinolone acetonide (2.5-5 mg/mL, 0.1 mL per lesion, maximum 20 mg per session). This reduces inflammation within 24-48 hours.
- •Avoid prolonged oral antibiotic use (>12 weeks) as it nearly doubles the 12-month relapse rate (46.3% vs 23.8%) and increases tetracycline resistance. Avoid non-dihydropyridine calcium channel blockers, topical corticosteroids, and comedogenic cosmetics.
- •Refer to a dermatologist if the patient fails to respond to 12 weeks of optimal therapy, requires isotretinoin, has severe scarring, or has a diagnosis of conglobate or fulminant acne.
- •Refer to endocrinology if hyperandrogenism is suspected; to psychiatry if depression or anxiety are identified on screening.
- •Educate patients on non-comedogenic skincare: use a mild cleanser (pH 4.7-5.75), apply a non-comedogenic moisturizer, and use sunscreen daily to prevent postinflammatory hyperpigmentation.
- •For women with acne and signs of hyperandrogenism, consider hormonal therapy: spironolactone 50-100 mg once daily (monitor potassium) or combined oral contraceptive pills (e.g., ethinyl estradiol/drospirenone).
- •Advise patients that improvement takes 4-8 weeks with topical therapies and 8-12 weeks with oral antibiotics; adherence is critical. Isotretinoin typically requires 20 weeks for a full course.
Board Review — High Yield
- •Four pillars of pathogenesis, Follicular hyperkeratinization, sebum overproduction, C. acnes colonization, and inflammation.
- •European severity scale, Grade 1 (comedonal), Grade 2 (mild-moderate papulopustular), Grade 3 (severe papulopustular/moderate nodular), Grade 4 (severe nodular/conglobate).
- •First-line for mild acne, Topical retinoid (adapalene 0.1% gel) ± benzoyl peroxide.
- •First-line for moderate inflammatory acne, Fixed-dose adapalene/BPO plus oral doxycycline for 8-12 weeks.
- •Isotretinoin protocol, 0.5-1 mg/kg/day to cumulative 120-150 mg/kg; requires pregnancy prevention and monitoring of lipids/LFTs.
- •Maintenance therapy, Continue adapalene/BPO or BPO alone for 24 weeks; reduces relapse from 52.6% to 10.8%.
- •Antibiotic stewardship, Limit oral antibiotics to 12 weeks; prolonged use increases relapse and resistance.
- •Comorbidity screening, Acne associated with depression (r=0.22) and anxiety (r=0.25); consider PHQ-9.
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
No articles were found for this section.
Pearl: Definition, Classification and Nomenclature is a core element of this topic; weigh it against the sections above.
Pathophysiology and Mechanism
No articles were found for this section.
Pearl: Pathophysiology and Mechanism is a core element of this topic; weigh it against the sections above.
Epidemiology, Etiology and Risk Factors
No articles were found for this section.
Pearl: Epidemiology, Etiology and Risk Factors is a core element of this topic; weigh it against the sections above.
Clinical Presentation
No articles were found for this section.
Pearl: Clinical Presentation is a core element of this topic; weigh it against the sections above.
Clinical and Dermoscopic Diagnosis
No articles were found for this section.
Pearl: Clinical and Dermoscopic Diagnosis is a core element of this topic; weigh it against the sections above.
Dermatopathology, Immunofluorescence and Laboratory Diagnosis
- ▸Acne vulgaris is diagnosed clinically; no histopathologic or laboratory test is required for typical cases.
- ▸Standardized skin surface biopsy can detect Demodex infestation, which is significantly more common in acne patients than in healthy controls.
- ▸Microbiome sampling methods significantly influence results, but microbiome analysis is not a clinical diagnostic tool.
Following the clinical and dermoscopic assessment, the diagnosis of acne vulgaris is confirmed at the bedside without the need for histopathologic or laboratory confirmation in typical cases. Acne vulgaris is clinically characterized by the presence of comedones, inflammatory papules/pustules, or nodules in the follicular areas, especially on the face [3]A1b. No single laboratory test, biopsy, or immunofluorescence study is required for routine diagnosis; these modalities are reserved for atypical presentations, suspected mimics, or research contexts.
Gold-Standard Diagnostic Test: Clinical Examination
The gold standard for diagnosing acne vulgaris is the clinical history and physical examination. The presence of comedones (open and closed), inflammatory papules, pustules, nodules, and cysts in a distribution involving the face, chest, and back, typically in an adolescent or young adult, is diagnostic. No imaging, serologic, or histopathologic test surpasses clinical judgment in typical cases.
Histopathology
Histopathologic evaluation is not indicated for routine acne vulgaris. When performed, for example, to exclude , , or cutaneous lymphoma, the biopsy shows follicular hyperkeratinization, distention of the pilosebaceous unit, and perifollicular inflammation. The provided evidence does not report specific histologic hallmarks from controlled studies; therefore, no further detail can be stated from the available literature. In practice, a punch biopsy of an inflammatory lesion may reveal a ruptured follicle with a mixed neutrophilic and lymphohistiocytic infiltrate, but this is not required for diagnosis.
Laboratory Studies and Microbiologic Sampling
Laboratory evaluation is not needed for diagnosis. However, in selected cases, standardized skin surface biopsy (SSSB) can be used to assess Demodex mite density, as Demodex infestation rates are significantly higher in acne vulgaris patients than in healthy controls (p = 0.001) [19]B3b. In one case-control study, Demodex infestation was found in 43 patients with acne vulgaris and was significantly more common than in controls, though no difference was observed between acne vulgaris and seborrheic dermatitis groups (p = 0.294) [19]B3b. SSSB is a practical tool for determining Demodex infestation when a superimposed demodicosis is suspected [19]B3b.
Microbiome analysis is not a diagnostic tool but is used in research. Sampling method significantly affects results: swabbing, modified standardized skin surface biopsy, and individual comedo extraction yield different bacterial and fungal profiles, with Staphylococcus spp. and Malassezia spp. being most affected by method (P < 0.05) [13]C4. This variation underscores the importance of standardized sampling for microbiome studies, but does not inform clinical diagnosis [13]C4.
Diagnostic Algorithm
Step 1: Clinical recognition of the characteristic lesion types and distribution. Step 2: If presentation is typical, the diagnosis is made; no further testing is required. Step 3: If atypical (e.g., unilateral, perioral distribution, absence of comedones, or persistent adult-onset), consider skin biopsy to rule out rosacea, folliculitis, or other conditions, and consider standardized skin surface biopsy for Demodex evaluation.
Special Considerations
- Demodex infestation: Significantly higher in acne vulgaris than controls (p = 0.001) [19]B3b. SSSB is a practical diagnostic tool when demodicosis is suspected.
- Microbiome sampling: If microbiome analysis is performed for research, the sampling method must be standardized because results vary significantly with swabbing, surface biopsy, or comedo extraction [13]C4.
- Lipidomics and skin barrier: Acne patients have altered skin surface lipid composition and reduced skin barrier function (e.g., increased transepidermal water loss, decreased moisture), but these are not diagnostic tests [15]C4.
Pearl: The diagnosis of acne vulgaris is made clinically; histopathology and laboratory testing are reserved for atypical presentations to exclude mimics such as rosacea, folliculitis, or Demodex-associated inflammation.
Severity Scoring and Risk Stratification
- ▸Severity classification in acne remains non-standardized; the European S3 four-point scale and the FDA IGA offer complementary approaches.
- ▸The 'very severe' designation is reserved for cystic/conglobate acne, allowing a tiered approach to topical vs. systemic therapy.
- ▸Relapse risk factors include severe seborrhea, young age, family history, prepubertal onset, and truncal acne; IGF-1 192-bp homozygosity adds a genetic dimension.
Once the diagnosis of acne vulgaris is established, the next clinical imperative is to classify severity, a step that directly gates every therapeutic escalation, from topical monotherapy to systemic isotretinoin. Despite decades of clinical use, there is no universally accepted grading system [21]A1c. Most clinicians rely on a global gestalt of mild, moderate, or severe, but these categories are subjective and may not capture the nuances that determine optimal treatment [21]A1c.
Grading Systems
Lesion counts offer a more objective metric and are standard in clinical trials, where they are paired with an Investigator Global Assessment (IGA) [21]A1c. However, counts alone do not convey lesion size or visibility, which can influence both treatment choice and patient distress [21]A1c. The 2016 European S3 Acne Guideline proposed a practical four-point classification that integrates lesion type and extent [21]A1c:
| Grade | Description |
|---|---|
| 1 | Comedonal acne |
| 2 | Mild-moderate papulopustular acne |
| 3 | Severe papulopustular acne, moderate nodular acne |
| 4 | Severe nodular acne, conglobate acne |
The US FDA-recommended IGA scale similarly grades severity by lesion quality and quantity, and it separates severe acne from nodular/conglobate disease [21]A1c.
Proposed Refinements
Recent advances in topical therapy have created a therapeutic gap: how to classify patients who may benefit from a potent topical combination rather than immediate oral isotretinoin [21]A1c. The Global Alliance consensus proposes reserving the designation "very severe" for cystic/conglobate acne, while recognizing that severe inflammatory acne (Grade 3 on the European scale or Grade 4 on the FDA scale) may now be managed with high-concentration topical retinoid-benzoyl peroxide combinations [21]A1c.
Risk Stratification for Relapse and Comorbidities
Beyond static severity, several factors predict a higher risk of relapse after treatment. These include severe seborrhea, young age, family history of acne, prepubertal onset, and truncal involvement [21]A1c. Genetic risk markers are emerging: homozygosity for the 192-bp allele of the gene promoter confers a 4.29-fold odds of having acne (95% CI 1.38-13.33) and a 3.08-fold odds of higher severity grade (95% CI 1.15-8.31) [35]B3b. Psychological comorbidity is also linked to severity: patients requiring systemic have a twofold increased odds of screening positive for symptoms [37]C4.
Pearl: The European four-point classification and the FDA IGA provide complementary frameworks; using both lesion type (comedonal vs. papulopustular vs. nodular) and a global severity grade ensures that treatment selection, from topical retinoid-BPO to systemic isotretinoin, is evidence-aligned.
| Grade | Description |
|---|---|
| 1 | Comedonal acne |
| 2 | Mild-moderate papulopustular acne |
| 3 | Severe papulopustular acne, moderate nodular acne |
| 4 | Severe nodular acne, conglobate acne |
Dermatologic Emergencies and Acute Management
No articles were found for this section.
Pearl: Dermatologic Emergencies and Acute Management is a core element of this topic; weigh it against the sections above.
Long-term and Definitive Management (Topical to Phototherapy to Systemic/Biologic Ladder)
No articles were found for this section.
Pearl: Long-term and Definitive Management (Topical to to Systemic/Biologic Ladder) is a core element of this topic; weigh it against the sections above.
History and Evolution of Treatment
No articles were found for this section.
Pearl: History and Evolution of Treatment is a core element of this topic; weigh it against the sections above.
Procedural and Surgical Dermatology
- ▸Modified PDT (low-concentration ALA, short incubation) provides rapid lesion reduction (1 week to 50% improvement) and is a safe alternative to isotretinoin, with no systemic side effects.
- ▸Dual-wavelength 589/1319 nm SSDW laser synergistically reduces inflammation (589 nm) and sebum production (1319 nm), achieving 46% ILC reduction as adjunct to BPO, with minimal pain (3.4/10) and no downtime.
- ▸Current evidence does not support delaying energy-based devices in patients receiving or recently completed isotretinoin; combination therapy appears safe and effective for acne and scarring.
Building on the evolution of systemic and topical therapies, a growing body of evidence supports energy-based and intralesional procedures as effective adjuncts or alternatives, particularly for patients with intolerance, resistance, or who desire rapid clearance. This section reviews the major procedural modalities, photodynamic therapy (PDT), vascular and dual-wavelength lasers, fractional CO₂ lasers, and intralesional injections, with emphasis on efficacy, safety, and practical parameters.
Photodynamic Therapy (PDT)
PDT uses a photosensitizer (e.g., 5-aminolevulinic acid [ALA], methyl aminolevulinate [MAL], indocyanine green [ICG], riboflavin) activated by a specific light wavelength to target sebaceous glands, reduce Cutibacterium acnes, and modulate inflammation [41]B2a[46]A1c. The most common protocols are:
- Conventional PDT (C-PDT): 5-20% ALA, incubation 1-3 hours, then red (630 nm) or blue light (450 nm). Effective but causes significant pain, erythema, and hyperpigmentation [46]A1c.
- Modified PDT (M-PDT): Lower ALA concentration (3-5%), shorter incubation (30 min), lower irradiance but prolonged illumination (630 nm, 40-60 mW/cm², 150 J/cm²). Reduces pain while maintaining efficacy; recommended by Chinese guidelines [46]A1c.
- Daylight PDT (DL-PDT): Minimal discomfort, requires sunny weather; less studied in acne.
A systematic review of 82 studies (4340 patients, mean age 24.4 years, 52% female) reported that no patient achieved a complete response; a partial response was observed across all treated patients, with inflammatory lesions responding better than non-inflammatory lesions [41]B2a. A network meta-analysis of 21 RCTs (898 participants) ranked ICG + near-infrared (NIR) diode laser as the most effective PDT regimen for both inflammatory and non-inflammatory lesions (SUCRA 84.4% and 93.5%, respectively) [50]A1a.
Comparative efficacy - M-PDT vs. isotretinoin: In a multicenter RCT (152 patients), M-PDT (up to 5 weekly sessions after manual comedone extraction) had a significantly higher effective rate at 1 month (67.74% vs. 10.26%, p < 0.001), while isotretinoin (0.5 mg/kg/d for 6 months) was superior at 6 months (75.81% vs. 97.44%) [44]A1b. Time to 50% lesion improvement was 1 week for M-PDT vs. 8 weeks for isotretinoin [44]A1b. Systemic side effects (hepatotoxicity) occurred in 70.67% of the isotretinoin group, while M-PDT side effects were skin-limited [44]A1b.
Riboflavin-PDT (blue-light activated) demonstrated non-inferiority to ALA-PDT for mild-to-moderate acne, with significantly less pain, burning, erythema, hyperpigmentation, and desquamation (p < 0.01 for all) [57]A1b.
Blue laser (450 nm) vs. red LED (630 ± 10 nm) PDT: In a split-face study (16 patients, moderate-to-severe acne), both modalities achieved similar improvement rates: 48.0% vs. 42.2% for total lesions, 63.0% vs. 58.1% for inflammatory lesions (p = NS). However, blue laser PDT caused more severe pain and hyperpigmentation [58]B2b.
Combination PDT + supramolecular salicylic acid (SSA): A prospective split-face study (19 patients) found that ALA-PDT followed by 30% SSA significantly reduced lesion counts, especially comedones and papules, and attenuated post-PDT erythema compared to PDT alone [54]A1b.
Laser Therapies
Lasers target one or more pathogenic mechanisms: inflammation (via vasculature), sebum production (via photothermolysis of sebaceous glands), and tissue remodeling.
| Laser Type | Wavelength | Mechanism | Key Efficacy Data |
|---|---|---|---|
| Pulsed dye laser (PDL) | 585-595 nm | Targets hemoglobin → reduces inflammation; stimulates TGF-β | Up to 82.5% reduction in inflammatory lesions [47]B2a |
| Nd:YAG (long-pulsed) | 1064 nm | Deeper penetration; targets sebaceous glands, reduces sebum, and stimulates collagen | Comparable to 577 nm diode laser; excellent ASI response in 28.8% [52]A1b; prolonged effect over intralesional TXA [42]A1b and BTX-A [45]A1b |
| Diode laser | 577 nm, 1450 nm, 1726 nm | Selective photothermolysis of sebaceous glands; 1726 nm has peak sebum/water absorption ratio [47]B2a | 1450 nm diode laser: 30-40% reduction in casual sebum level (CSL) [48]B2a; 1726 nm: 56% ILC reduction as monotherapy, 79.8% achieve ≥50% ILC reduction with 3 sessions [47]B2a |
| Dual-wavelength 589/1319 nm (SSDW) | 589 nm (vascular) + 1319 nm (water/sebaceous) | 589 nm reduces inflammation; 1319 nm decreases sebum, stimulates neocollagenesis | Adjunctive to BPO: 46% ILC reduction at 3 months (vs. 29% BPO alone, p = 0.008) [3]A1b; 72% response rate for acne erythema at 8-week follow-up [51]A1b; pain score 3.4/10, no serious AEs [3]A1b |
| Fractional CO₂ laser | 10,600 nm | Ablative; creates microchannels for comedone evacuation and drug delivery | 64.49% comedone reduction vs. 46.36% with comedone extractor (p < 0.001) [59]A1b; combined with 30% SSA: 85.76% comedone reduction (vs. 62.32% CO₂ alone) [43]A1b; improves acne scar severity and quality of life [55]A1b |
| 1064 nm picosecond laser with micro-lens array (P-MLA) | 1064 nm | Fractional photomechanical effect; reduces post-acne erythema | Superior to ELOS for PAE lesion counts and clinical response at week 12 (p < 0.05); overall satisfaction 94.74% [56]A1b |
Combination vascular lasers: PDL + Nd:YAG (595 nm + 1064 nm) achieved up to 83.5% reduction in inflammatory lesions [47]B2a.
Safety of lasers with isotretinoin: A systematic review of 16 studies (including 6 RCTs) concluded that current evidence does not justify delaying energy-based devices (PDL, NAFL, FMRF, IPL) for patients on or recently completed isotretinoin; no increased risk of keloid or delayed wound healing was observed [49]B2a.
Intralesional Injections
Intralesional tranexamic acid (TXA): In a split-face study (30 patients), 4 sessions of intralesional TXA at 2-week intervals significantly reduced IGA, lesion count, and erythema score (p < 0.001). However, 1064 nm Nd:YAG laser had a more prolonged therapeutic effect at 3-month follow-up [42]A1b. TXA was described as a promising "lunch-time procedure" [42]A1b.
Intralesional botulinum toxin type A (BTX-A): Monthly injections (up to 3 sessions) achieved significant improvement in inflammatory lesions, comparable to Nd:YAG laser at end of treatment, but Nd:YAG laser had more sustained efficacy and lower recurrence at 3-month follow-up [45]A1b.
Ethosome gold nanoparticle photothermal therapy: Pretreatment with CO₂ fractional laser, followed by topical gold nanoparticle ampule and long-pulsed Nd:YAG laser (1064 nm, 4.5 J/cm²), showed significant reductions in all lesion types and improved acne scars in a preliminary study of 24 patients with moderate-to-severe acne [53]C4.
Adverse Events and Practical Considerations
- PDT: Pain, burning, erythema are common; M-PDT and DL-PDT reduce these. Transient hyperpigmentation, especially with blue-light PDT [58]B2b.
- Lasers: Pain (mean VAS 3.4 / 10 for SSDW [3]A1b; 4.9 / 10 for 1726 nm diode [47]B2a); mild erythema, dryness, peeling that resolve within 2 weeks [3]A1b. Transient acne flare-up may occur with NIR lasers (e.g., 1319 nm, 1726 nm) [3]A1b.
- Intralesional injections: Pain at injection site, minimal systemic effects.
Pearl: For patients with moderate-to-severe acne who decline or cannot tolerate isotretinoin, modified PDT (3-5% ALA, 30 min incubation, red light 630 nm, 150 J/cm²) offers a rapid onset (1 week to 50% improvement) with excellent tolerability, and can be combined with a 30% supramolecular salicylic acid peel to enhance comedone clearance and reduce post-PDT erythema [44]A1b[54]A1b.
| Laser Type | Wavelength | Mechanism | Key Efficacy Data |
|---|---|---|---|
| Pulsed dye laser (PDL) | 585-595 nm | Targets hemoglobin → reduces inflammation; stimulates TGF-β | Up to 82.5% reduction in inflammatory lesions [47]B2a |
| Nd:YAG (long-pulsed) | 1064 nm | Deeper penetration; targets sebaceous glands, reduces sebum, stimulates collagen | Excellent ASI response in 28.8% [52]A1b; prolonged effect over intralesional TXA [42]A1b and BTX-A [45]A1b |
| Dual-wavelength SSDW | 589/1319 nm | 589 nm: vascular; 1319 nm: water/sebaceous → neocollagenesis | Adjunctive to BPO: 46% ILC reduction at 3 months [3]A1b; 72% response for acne erythema [51]A1b |
| Fractional CO₂ laser | 10,600 nm | Ablative microchannels for comedone evacuation and drug delivery | 64.49% comedone reduction vs. 46.36% with extractor [59]A1b; 85.76% comedone reduction with 30% SSA [43]A1b |
| Picosecond 1064 nm (P-MLA) | 1064 nm | Fractional photomechanical effect | Superior to ELOS for post-acne erythema; 94.74% satisfaction [56]A1b |
| PDT Modality | Photosensitizer | Light Source | Key Efficacy | Adverse Effects |
|---|---|---|---|---|
| Conventional PDT (C-PDT) | 5-20% ALA, 1-3 h incubation | Red (630 nm) or blue (450 nm) light | Effective, but high pain | Severe pain, erythema, hyperpigmentation [46]A1c |
| Modified PDT (M-PDT) | 3-5% ALA, 30 min incubation | 630 nm, 40-60 mW/cm², 150 J/cm² | 67.74% effective at 1 month; time to 50% improvement: 1 week [44]A1b | Minimal pain, skin-limited erythema [44]A1b |
| Daylight PDT (DL-PDT) | ALA | Sunlight | Limited data; <1% of patients in systematic review [41]B2a | Minimal discomfort |
| ICG + NIR diode laser | Indocyanine green | 830 nm NIR diode | Highest SUCRA for inflammatory (84.4%) and non-inflammatory (93.5%) lesions [50]A1a | Not reported in meta-analysis |
| Riboflavin-PDT | Riboflavin | Blue light | Non-inferior to ALA-PDT; comparable improvement rates [57]A1b | Significantly less pain, burning, erythema, hyperpigmentation than ALA-PDT [57]A1b |
| Blue laser (450 nm) + ALA | ALA | 450 nm blue laser | 48.0% total lesion improvement; 63.0% inflammatory improvement [58]B2b | More severe pain and hyperpigmentation than red LED [58]B2b |
Complications and Comorbidities
No articles were found for this section.
Pearl: Complications and Comorbidities is a core element of this topic; weigh it against the sections above.
Prognosis and Natural History
- ▸Acne vulgaris is a chronic relapsing condition; spontaneous remission is uncommon and most patients require long-term disease control.
- ▸Recurrence rates increase with extended antibiotic duration: 23.8% (short-term) to 46.3% (prolonged) at 12 months, without improving acute success rates.
- ▸Maintenance therapy with adapalene/benzoyl peroxide 2.5% gel reduces relapse to 10.8% and prevents worsening of atrophic scarring.
Beyond these complications, acne vulgaris follows a chronic relapsing course, with natural history varying by severity, treatment, and individual host factors. Spontaneous complete remission is uncommon; most patients experience cycles of improvement and flare over years, with the condition persisting into adulthood in approximately 85% of adolescents [62]D5.
Recurrence Rates and Predictive Factors
Recurrence after treatment cessation is the rule, not the exception. The 12-month recurrence rate increases in a duration‑dependent manner with systemic antibiotic exposure: 23.8% with short-term (6-12 weeks), 35.0% with standard-term (13-16 weeks), and 46.3% with prolonged (17-24 weeks) therapy (p < 0.001) [71]B3b. Median recurrence‑free survival falls from 9.2 months to 6.9 months with prolonged (adjusted HR 2.31, 95% CI 1.31-4.07) [71]B3b. Tetracycline resistance also rises with prolonged use (42.9% vs 13.3-17.6%, p = 0.032) [71]B3b.
| Treatment Context | Recurrence Rate | Follow-up Period | Source |
|---|---|---|---|
| Short-term antibiotic (6-12 wk) | 23.8% | 12 months | [71]B3b |
| Standard-term antibiotic (13-16 wk) | 35.0% | 12 months | [71]B3b |
| Prolonged antibiotic (17-24 wk) | 46.3% | 12 months | [71]B3b |
| No maintenance therapy (control) | 52.6% failure* | 24 weeks | [67]A1b |
| Adapalene/BPO maintenance | 10.8% failure* | 24 weeks | [67]A1b |
| Visible light therapy | 92% partial remission | Mean 4 weeks | [63]D5 |
*Failure defined as inability to maintain inflammatory lesions ≤10.
Maintenance Therapy and Scar Prevention
Continuing topical therapy after inflammation subsides dramatically reduces relapse. Maintenance with adapalene 0.1%/benzoyl peroxide 2.5% gel achieves a success rate of 89.2% (lesions ≤10) versus 47.4% in untreated controls (p = 0.0006) [67]A1b. Importantly, maintenance also prevents progression of atrophic scarring: the control group showed significant worsening in scar area, volume, and depth at 24 weeks (p = 0.0276, 0.0445, 0.0182), while treated groups did not [67]A1b.
Impact of Isotretinoin Dose
Conventional-dose isotretinoin (0.5-1.0 mg/kg/day to cumulative 120-150 mg/kg) improves the odds of prolonged remission compared with low-dose regimens [64]A1a. Low-dose isotretinoin (0.1-0.3 mg/kg/day for >6 months) produces fewer side effects but higher relapse rates [65]A1a.
Procedural and Light-Based Therapies
Fractional microneedling radiofrequency has lower recurrence rates than lasers or conventional radiofrequency [69]B2a. The 1550‑nm erbium glass laser produces significant reduction in lesion counts and sebaceous gland size, with sustained effect over 1‑year follow‑up [61]A1b. Visible light therapy achieves 92% partial remission, with mean onset at 4 weeks [63]D5.
Pearl: The strongest modifiable predictor of recurrence is antibiotic duration >12 weeks, which nearly doubles the 12‑month relapse rate without improving short‑term clearance; maintenance with adapalene/BPO after antibiotic cessation is the most effective strategy to prevent both relapse and scar progression [71]B3b[67]A1b.
Special Populations and Pregnancy
No articles were found for this section.
Pearl: Special Populations and Pregnancy is a core element of this topic; weigh it against the sections above.
Prevention, Screening and Surveillance
- ▸Maintenance therapy with adapalene 0.1%/BPO 2.5% gel or BPO 2.5% gel alone significantly reduces relapse and prevents atrophic scar progression over 24 weeks [67][77].
- ▸Sunscreen use is essential for primary prevention of postinflammatory hyperpigmentation, especially in skin of color [78][80].
- ▸Clinicians should screen for depression and anxiety in all patients with acne, given the strong association reported in meta-analysis (r = 0.22 for depression, r = 0.25 for anxiety) [89].
Building on the special considerations for pregnancy and pediatric populations, prevention in acne vulgaris centers on sustaining remission, minimizing scarring, and avoiding antibiotic resistance. Primary prevention strategies target modifiable risk factors. The 2024 international expert consensus on dermocosmetics recommends that all patients with acne use appropriate cleansers, moisturizers, and sunscreens, as these products improve barrier function, reduce oiliness, and prevent postinflammatory hyperpigmentation, especially in darker skin phototypes [78]A1c. Sunscreen is essential; the same consensus advises photoprotection “as appropriate for the season and climate” to reduce acne-induced hyperpigmentation [78]A1c. A 2024 phase IV study of trifarotene 50 μg/g cream plus a skincare regimen (including sunscreen) showed significantly better improvement in the post-acne hyperpigmentation index at week 24 (-18.9% vs. -11.3% with vehicle, P < 0.01) [80]A1b.
Secondary Prevention: Maintenance Therapy to Prevent Flares
Once acute inflammation is controlled, maintenance therapy is the cornerstone of secondary prevention. The 2017 Japanese Dermatological Association guidelines specifically recommend limiting antimicrobial treatments to the acute inflammatory phase (approximately 3 months) and using benzoyl peroxide (BPO), adapalene, or a fixed-dose combination of adapalene 0.1%/BPO 2.5% for the maintenance phase to avoid emergence of antimicrobial-resistant Cutibacterium acnes [79]A1c. A systematic review of acne guidelines (2017-2021) confirmed consensus that topical treatments should be continued as maintenance therapy [81]D5.
Key evidence for specific maintenance regimens:
| Maintenance Regimen | Key Evidence | NNT (if calculable) |
|---|---|---|
| Adapalene 0.1%/BPO 2.5% gel once daily | 78.9% maintained ≥50% improvement at 24 weeks vs. 45.8% vehicle (P < 0.001) [77]A1b; time to 25% relapse: 175 days vs. 56 days [77]A1b | NNT = 3 to prevent one relapse over 24 weeks (calculated from 78.9% vs 45.8%) |
| Adapalene 0.1%/BPO 2.5% gel or BPO 2.5% gel alone | Treatment success (inflammatory lesions ≤10) at 24 weeks: 89.2% (A/BPO) and 87.5% (BPO) vs. 47.4% control (P = 0.0006) [67]A1b | NNT = 2.4 for A/BPO; NNT = 2.5 for BPO based on success rates |
| Adapalene gel 0.1% once daily | Maintenance rate for total lesions: 84.7% vs. 63.5% vehicle (P = 0.0049) after 12 weeks [88]A1b | NNT = 5 |
| Clindamycin phosphate 1.2%/BPO 3.75% gel once daily | Mean inflammatory lesion reduction 93.8% at 24 weeks; 72% clear/almost clear [84]C4 | NNT not calculable from reported data |
| Dapsone 5% gel twice daily | 82% maintained IGA response at week 24 after -dapsone combination [85]C4 | NNT not calculable from reported data |
A 2014 meta-analysis of adapalene-BPO combination gel confirmed superior success rates compared with vehicle (P < 0.00001) and greater overall satisfaction (P = 0.005) [90]A1a. Importantly, maintenance therapy also reduces atrophic scarring: a 2023 study showed significant improvement in scar number at 24 weeks with adapalene/BPO or BPO alone, while the control group experienced significant worsening of scar volume and depth (P = 0.0182 for maximum depth) [67]A1b.
Screening Recommendations
- Depression and anxiety: A 2020 meta-analysis of 42 studies found a significant association between acne vulgaris and depression (r = 0.22, 95% CI 0.17-0.26, P < 0.00001) and anxiety (r = 0.25, 95% CI 0.19-0.31, P < 0.00001). The authors recommend that clinicians “pursue aggressive treatment of acne and consider psychiatric screening or referrals” [89]A1a.
- Endocrinopathy in preadolescents: For children aged 2-7 years presenting with acne, the 2013 recommendations suggest a focused history and physical examination; hand X-ray for bone age is a useful screening test, and endocrinology referral is warranted if bone age is advanced or additional clinical signs of early puberty are present [91]C4.
Vaccine-Related Considerations
Acne vaccines targeting Cutibacterium acnes are under investigation but not yet clinically available. In 2018, a study demonstrated that vaccination with C. acnes CAMP factor reduced bacterial growth and inflammation in mice, and monoclonal antibodies against CAMP factor attenuated IL-8 and IL-1β in human ex vivo acne explants [7]D5. Earlier work (2008) showed that intranasal immunization with heat-inactivated C. acnes vaccines elicited protective immunity in mice and neutralized cytotoxicity in human sebocytes [8]D5. These are promising experimental strategies, but no vaccine is currently recommended for clinical use.
Patient Education Points
- Avoid traditional soaps (pH 10-11); use synthetic detergents or lipid-free cleansers with pH between 4.7 and 5.75 [78]A1c.
- Apply sunscreen daily to prevent postinflammatory hyperpigmentation, especially in skin of color [78]A1c[80]A1b.
- Continue maintenance therapy for at least 6 months after acute treatment to prevent relapse and reduce scarring [77]A1b[67]A1b.
- Do not use topical or oral as monotherapy; always combine with a non-antibiotic topical agent [81]D5[79]A1c.
Pearl: Maintenance therapy with adapalene/BPO or BPO alone for 24 weeks reduces the risk of relapse by roughly 40% (NNT ≈ 3) and prevents worsening of atrophic scars, making it as important as the initial acute treatment [67]A1b[77]A1b.
| Regimen | Evidence Summary | NNT (if calculable) |
|---|---|---|
| Adapalene 0.1%/BPO 2.5% gel once daily | 78.9% maintenance success at 24 weeks vs 45.8% vehicle; median time to 25% relapse 175 days [77]A1b | 3 to prevent one relapse over 24 weeks |
| Adapalene 0.1%/BPO 2.5% gel or BPO 2.5% gel alone | 89.2% and 87.5% success (inflammatory lesions ≤10) vs 47.4% control at 24 weeks; significant scar prevention [67]A1b | 2.4 (A/BPO); 2.5 (BPO) |
| Adapalene gel 0.1% once daily | 84.7% maintenance rate vs 63.5% vehicle at 12 weeks [88]A1b | 5 |
| Clindamycin 1.2%/BPO 3.75% gel once daily | 93.8% reduction in inflammatory lesions at 24 weeks; 72% clear/almost clear [84]C4 | Not calculable from reported data |
| Dapsone 5% gel twice daily | 82% maintained IGA response at 24 weeks after doxycycline-dapsone combination [85]C4 | Not calculable from reported data |
References
- [1]
Ray Jalian H, Tam J, Vuong LN et al.. “Selective Cryolysis of Sebaceous Glands.” The Journal of investigative dermatology (2015). PMID: 25860384 ↗
L4NON_RANDOMIZED_TRIALCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [2]
Hay RJ, Johns NE, Williams HC et al.. “The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.” The Journal of investigative dermatology (2013). PMID: 24166134 ↗
L2CROSS_SECTIONALCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [3]
Boonpethkaew S, Ratanapokasatit Y, Chirasuthat S et al.. “Efficacy and safety of the 589/1319 nm solid-state dual-wavelength laser combined with topical benzoyl peroxide for inflammatory acne vulgaris: a split-face randomized controlled trial.” Archives of dermatological research (2025). PMID: 40140055 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis, Procedural and Surgical Dermatology - [4]
Samadi A, Sartipi Z, Ahmad Nasrollahi S et al.. “Efficacy assessments of tretinoin-loaded nano lipid carriers in acne vulgaris: a double blind, split-face randomized clinical study.” Archives of dermatological research (2021). PMID: 34146120 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [5]
Paithankar DY, Sakamoto FH, Farinelli WA et al.. “Acne Treatment Based on Selective Photothermolysis of Sebaceous Follicles with Topically Delivered Light-Absorbing Gold Microparticles.” The Journal of investigative dermatology (2015). PMID: 25748556 ↗
L4NARRATIVE_REVIEWCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [6]
Xia X, Li Z, Liu K et al.. “Staphylococcal LTA-Induced miR-143 Inhibits Propionibacterium acnes-Mediated Inflammatory Response in Skin.” The Journal of investigative dermatology (2015). PMID: 26739093 ↗
L5OTHERCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [7]
Wang Y, Hata TR, Tong YL et al.. “The Anti-Inflammatory Activities of Propionibacterium acnes CAMP Factor-Targeted Acne Vaccines.” The Journal of investigative dermatology (2018). PMID: 29964032 ↗
L5OTHERCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis, Prevention, Screening and Surveillance - [8]
Nakatsuji T, Liu YT, Huang CP et al.. “Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris.” The Journal of investigative dermatology (2008). PMID: 18463682 ↗
L5OTHERCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis, Prevention, Screening and Surveillance - [9]
Lee JH, Kim DH, Yoon JY et al.. “Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study.” Italian journal of dermatology and venereology (2024). PMID: 39069843 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [10]
Kim J, Lee SG, Choi S et al.. “Combination of Fractional Microneedling Radiofrequency and Ablative Fractional Laser versus Ablative Fractional Laser Alone for Acne and Acne Scars.” Yonsei medical journal (2023). PMID: 37992744 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [11]
Li S, He X, Zhang Z et al.. “Efficacy and safety of a facial serum and a mask containing salicylic acid and lipohydroxy acid in acne management: A randomized controlled trial.” Journal of cosmetic dermatology (2023). PMID: 36999489 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [12]
Kulthanan K, Trakanwittayarak S, Tuchinda P et al.. “A Double-Blinded, Randomized, Vehicle-Controlled Study of the Efficacy of Moisturizer Containing Licochalcone A, Decanediol, L-Carnitine, and Salicylic Acid for Prevention of Acne Relapse in Asian Population.” BioMed research international (2020). PMID: 33150170 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [13]
Xu DT, Chen Q, Yang JY et al.. “A noteworthy issue: microbiome data variation depending on sampling methods in skin microecology studies in acne vulgaris patients.” Frontiers in immunology (2025). PMID: 40552289 ↗
L4NON_RANDOMIZED_TRIALCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [14]
Manurung THP, Sitohang IBS, Agustin T. “Staphylococcus caprae and Staphylococcus epidermidis define the skin microbiome among different grades of acne vulgaris.” Archives of dermatological research (2024). PMID: 39738874 ↗
L4COHORTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [15]
Cheng Y, Sun Q, Gao J et al.. “Quantitative lipidomics profiling of skin surface lipids and skin barrier function evaluation in patients with acne vulgaris.” Archives of dermatological research (2025). PMID: 39912955 ↗
L4CASE_CONTROLCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [16]
Guerra-Tapia A, Martínez H, Nieto C et al.. “A new topical biotechnological phytocomplex for truncal mild-moderate acne restores skin microbiota balance.” Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) (2024). PMID: 39044362 ↗
L4NON_RANDOMIZED_TRIALCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [17]
Rajaiah Yogesh H, Gajjar T, Patel N et al.. “Clinical study to assess efficacy and safety of Purifying Neem Face Wash in prevention and reduction of acne in healthy adults.” Journal of cosmetic dermatology (2021). PMID: 34590784 ↗
L4NON_RANDOMIZED_TRIALCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [18]
Heng AHS, Chew FT. “Systematic review of the epidemiology of acne vulgaris.” Scientific reports (2020). PMID: 32238884 ↗
L2SR_COHORTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [19]
Aktaş Karabay E, Aksu Çerman A. “Demodex folliculorum infestations in common facial dermatoses: acne vulgaris, rosacea, seborrheic dermatitis.” Anais brasileiros de dermatologia (2020). PMID: 32113677 ↗
L3COHORTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [20]
Chilicka K, Rogowska AM, Szyguła R et al.. “A comparison of the effectiveness of azelaic and pyruvic acid peels in the treatment of female adult acne: a randomized controlled trial.” Scientific reports (2020). PMID: 32724156 ↗
L1RCTCited in: Dermatopathology, Immunofluorescence and Laboratory Diagnosis - [21]
Thiboutot DM, Dréno B, Abanmi A et al.. “Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne.” Journal of the American Academy of Dermatology (2017). PMID: 29127053 ↗
L1GUIDELINECited in: Severity Scoring and Risk Stratification - [22]
Taylor S, Elbuluk N, Grimes P et al.. “Treatment recommendations for acne-associated hyperpigmentation: Results of the Delphi consensus process and a literature review.” Journal of the American Academy of Dermatology (2023). PMID: 36924935 ↗
L1GUIDELINECited in: Severity Scoring and Risk Stratification - [23]
Dréno B, Bettoli V, Araviiskaia E et al.. “The influence of exposome on acne.” Journal of the European Academy of Dermatology and Venereology : JEADV (2018). PMID: 29377341 ↗
L5GUIDELINECited in: Severity Scoring and Risk Stratification - [24]
Song BH, Lee DH, Kim BC et al.. “Photodynamic therapy using chlorophyll-a in the treatment of acne vulgaris: a randomized, single-blind, split-face study.” Journal of the American Academy of Dermatology (2014). PMID: 24930587 ↗
L1RCTCited in: Severity Scoring and Risk Stratification - [25]
Gold LS, Dhawan S, Weiss J et al.. “A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies.” Journal of the American Academy of Dermatology (2018). PMID: 30165171 ↗
L1RCTCited in: Severity Scoring and Risk Stratification - [26]
Orringer JS, Kang S, Maier L et al.. “A randomized, controlled, split-face clinical trial of 1320-nm Nd:YAG laser therapy in the treatment of acne vulgaris.” Journal of the American Academy of Dermatology (2007). PMID: 17239987 ↗
L1RCTCited in: Severity Scoring and Risk Stratification - [27]
Kakpovbia EE, Young T, Milam EC et al.. “Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials.” Journal of the European Academy of Dermatology and Venereology : JEADV (2024). PMID: 38943431 ↗
L1SR_MA_RCTCited in: Severity Scoring and Risk Stratification - [28]
Eichenfield LF, DuBois JC, Gold MH et al.. “DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial.” Journal of the American Academy of Dermatology (2023). PMID: 37295506 ↗
L1RCT_PHASE2Cited in: Severity Scoring and Risk Stratification - [29]
Bissonnette R, Poulin Y, Drew J et al.. “Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study.” Journal of the American Academy of Dermatology (2016). PMID: 28029390 ↗
L1RCT_PHASE2Cited in: Severity Scoring and Risk Stratification - [30]
Richter C, Trojahn C, Hillmann K et al.. “Sensitivity to change of the Dermatology Life Quality Index in adult females with facial acne vulgaris: a validation study.” Journal of the European Academy of Dermatology and Venereology : JEADV (2016). PMID: 27393576 ↗
L2PROSPECTIVE_COHORTCited in: Severity Scoring and Risk Stratification - [31]
Le Y, Yang W, Lu J et al.. “Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase 3, multi-centre, randomized, double-blind, vehicle-controlled study.” Journal of the European Academy of Dermatology and Venereology : JEADV (2024). PMID: 38948962 ↗
L1RCTCited in: Severity Scoring and Risk Stratification - [32]
Başak PY, Cetin ES, Gürses I et al.. “The effects of systemic isotretinoin and antibiotic therapy on the microbial floras in patients with acne vulgaris.” Journal of the European Academy of Dermatology and Venereology : JEADV (2012). PMID: 22239608 ↗
L2RCTCited in: Severity Scoring and Risk Stratification - [33]
Jones-Caballero M, Chren MM, Soler B et al.. “Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment.” Journal of the European Academy of Dermatology and Venereology : JEADV (2007). PMID: 17243958 ↗
L2COHORTCited in: Severity Scoring and Risk Stratification - [34]
Dréno B, Thiboutot D, Layton AM et al.. “Large-scale international study enhances understanding of an emerging acne population: adult females.” Journal of the European Academy of Dermatology and Venereology : JEADV (2014). PMID: 25296739 ↗
L2COHORTCited in: Severity Scoring and Risk Stratification - [35]
Rahaman SMA, De D, Handa S et al.. “Association of insulin-like growth factor (IGF)-1 gene polymorphisms with plasma levels of IGF-1 and acne severity.” Journal of the American Academy of Dermatology (2016). PMID: 27476104 ↗
L3CASE_CONTROLCited in: Severity Scoring and Risk Stratification - [36]
Chen Q, Chen R, Wu L et al.. “Denifanstat for moderate-to-severe acne: A Phase 2, randomized, double-blind, placebo-controlled trial.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 41186280 ↗
L1RCT_PHASE2Cited in: Severity Scoring and Risk Stratification - [37]
Bowe WP, Leyden JJ, Crerand CE et al.. “Body dysmorphic disorder symptoms among patients with acne vulgaris.” Journal of the American Academy of Dermatology (2007). PMID: 17498840 ↗
L4CROSS_SECTIONALCited in: Severity Scoring and Risk Stratification - [38]
Yuan Y, Wang Y, Xia J et al.. “Topical, light-based, and complementary interventions for acne: an overview of systematic reviews.” The Cochrane database of systematic reviews (2024). PMID: 39440650 ↗
L1SR_MA_RCTCited in: Severity Scoring and Risk Stratification - [39]
Cao H, Yang G, Wang Y et al.. “Complementary therapies for acne vulgaris.” The Cochrane database of systematic reviews (2015). PMID: 25597924 ↗
L1SR_MA_RCTCited in: Severity Scoring and Risk Stratification - [40]
Kwon HH, Choi SC, Jung JY et al.. “A Novel Combined Light-Based Treatment of Acne Vulgaris With 1,450-nm Diode Laser and 450-nm Blue Light.” Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2019). PMID: 30789515 ↗
L1RCTCited in: Severity Scoring and Risk Stratification - [41]
Qureshi S, Rehan Z, Ao A et al.. “Photodynamic Therapy in Acne Vulgaris: A Systematic Review.” Journal of cutaneous medicine and surgery (2024). PMID: 39552358 ↗
L2SR_MA_RCTCited in: Procedural and Surgical Dermatology, Prognosis and Natural History - [42]
Eltanany HHM, Qawy FAWA, Hamdino M et al.. “A split face study comparing intralesional tranexamic acid versus 1064 nm long pulsed Nd: YAG laser for acne vulgaris treatment.” Archives of dermatological research (2025). PMID: 40221536 ↗
L1RCTCited in: Procedural and Surgical Dermatology, Prognosis and Natural History - [43]
Yang MY, Liu J, Ning DC et al.. “Combining superpulse dynamic CO2 laser and supramolecular salicylic acid in the treatment of dense comedones with higher clearance in a shorter time: A prospective, randomized, split-face clinical trial.” Lasers in surgery and medicine (2023). PMID: 37582350 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [44]
Zhang L, Yang Y, Wang B et al.. “Modified red light 5-aminolevulinic acid photodynamic therapy versus low-dose isotretinoin therapy for moderate to severe acne vulgaris: A prospective, randomized, multicenter study.” Journal of the American Academy of Dermatology (2023). PMID: 37558093 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [45]
Ibrahim AM, Omar GAB, Hamdino M. “Long-pulsed Nd: YAG laser (1064 nm) versus intralesional botulinum toxin type (A) in acne vulgaris therapy: a split face study.” International journal of dermatology (2022). PMID: 36468835 ↗
L1RCTCited in: Procedural and Surgical Dermatology, Prognosis and Natural History - [46]
Wang P, Wang B, Zhang L et al.. “Clinical practice Guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China.” Photodiagnosis and photodynamic therapy (2022). PMID: 36587863 ↗
L1GUIDELINECited in: Procedural and Surgical Dermatology - [47]
Jafarzadeh A, Heidari S, Omid R et al.. “Systematic review of vascular lasers for the treatment of inflammatory active acne vulgaris.” Lasers in medical science (2025). PMID: 40167813 ↗
L2SR_MA_RCTCited in: Procedural and Surgical Dermatology - [48]
Jaalouk D, Pulumati A, Algarin YA et al.. “The impact of energy-based devices on sebum in acne vulgaris: A systematic review.” Journal of cosmetic dermatology (2024). PMID: 39129257 ↗
L2SR_MA_RCTCited in: Procedural and Surgical Dermatology - [49]
Xu Y, Wang H, Guo L et al.. “Combinations of Energy-based Devices plus isotretinoin for management of acne and acne scars: A systematic review.” Journal of cosmetic dermatology (2024). PMID: 38845186 ↗
L2SR_MA_RCTCited in: Procedural and Surgical Dermatology - [50]
Long XX, Xie AD, Yang P et al.. “Effect of various types of photodynamic therapy on inflammatory and non-inflammatory lesions in patients with acne: A network meta-analysis of randomized controlled trials.” Photodiagnosis and photodynamic therapy (2023). PMID: 36842473 ↗
L1SR_MA_RCTCited in: Procedural and Surgical Dermatology - [51]
Boonpethkaew S, Anansiripun P, Maitrisathit W et al.. “Efficacy and Safety of a Dual-Wavelength 589/1319 nm Laser for the Treatment of Acne Erythema: A Split-Face Randomized Controlled Trial.” Journal of cosmetic dermatology (2026). PMID: 42087432 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [52]
Mohamed EM, Abdel-Aleem HL, Elazab GMH et al.. “Comparative efficacy and safety of 577-nm diode laser versus 1064-nm Nd: YAG laser for inflammatory acne vulgaris: a split-face randomized study.” Lasers in medical science (2025). PMID: 41071332 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [53]
Suh DH, Lee SJ, Kim H et al.. “Effect of CO2 Fractional Laser PreTreatment in Photothermal Therapy Using Ethosome Gold Nanoparticles: A Preliminary Study.” Journal of cosmetic dermatology (2025). PMID: 40654089 ↗
L4RCTCited in: Procedural and Surgical Dermatology - [54]
Yan Y, Wang D, Wang P et al.. “Effect of 5-aminolaevulinic acid photodynamic therapy followed by sequential 30% supramolecular salicylic acid treatment in moderate-to-severe acne vulgaris: a prospective, randomized, split-face controlled study.” Clinical and experimental dermatology (2025). PMID: 40420552 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [55]
Saki N, Alavizadeh S, Parvizi MM et al.. “Fractional CO2 laser alone versus combined with topical timolol or insulin for acne Scar treatment: a randomized controlled clinical trial.” Lasers in medical science (2025). PMID: 40259159 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [56]
Jing X, Ren J, Yang J. “Comparison of 1064-nm Nd: YAG picosecond laser with fractional micro-lens array and electro-optical synergy for post-acne erythema: a prospective, randomized, split-face trial.” Lasers in medical science (2025). PMID: 39907828 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [57]
Ding A, Shi L, Jiang F et al.. “Topical riboflavin versus 5-aminolevulinic acid photodynamic therapy for the treatment of mild to moderate acne: A split-face randomized study.” Photodiagnosis and photodynamic therapy (2024). PMID: 39709022 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [58]
Fan H, Tuo H, Xie Y et al.. “Comparison of blue laser and red light-emitting diode-mediated aminolevulinic acid-based photodynamic therapy for moderate and severe acne vulgaris: A prospective, split-face, nonrandomized controlled study.” Photodiagnosis and photodynamic therapy (2024). PMID: 39245305 ↗
L2RCTCited in: Procedural and Surgical Dermatology - [59]
Yang MY, Qiao SM, Ning DC et al.. “Treatment effect of ultra-pulse dynamic CO2 laser and comedone extractor in dense comedones: a prospective, randomized, split-face, evaluator-blind, controlled clinical trial.” Lasers in medical science (2024). PMID: 39235691 ↗
L1RCTCited in: Procedural and Surgical Dermatology - [60]
Deng Y, Feng R, Hu B et al.. “Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis.” Frontiers in pharmacology (2025). PMID: 40230697 ↗
L1SR_MA_RCTCited in: Prognosis and Natural History - [61]
Moneib H, Tawfik AA, Youssef SS et al.. “Randomized split-face controlled study to evaluate 1550-nm fractionated erbium glass laser for treatment of acne vulgaris--an image analysis evaluation.” Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2014). PMID: 25310750 ↗
L1RCTCited in: Prognosis and Natural History - [62]
Visser WI, Kannenberg SM, Prevost A et al.. “Dermocosmetics in Acne Vulgaris: South African Consensus Recommendations With a Focus on Skin of Color.” Journal of cosmetic dermatology (2026). PMID: 41689191 ↗
L5GUIDELINECited in: Prognosis and Natural History, Prevention, Screening and Surveillance - [63]
Akuffo-Addo E, Ramsay K, Mohsen S et al.. “Visible Light in the Treatment of Acne Vulgaris.” Journal of cutaneous medicine and surgery (2024). PMID: 39056372 ↗
L5SR_COHORTCited in: Prognosis and Natural History - [64]
Al Muqarrab F, Almohssen A. “Low-dose oral isotretinoin for the treatment of adult patients with mild-to-moderate acne vulgaris: Systematic review and meta-analysis.” Dermatologic therapy (2022). PMID: 35000295 ↗
L1SR_COHORTCited in: Prognosis and Natural History - [65]
Sadeghzadeh-Bazargan A, Ghassemi M, Goodarzi A et al.. “Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies.” Dermatologic therapy (2020). PMID: 33085149 ↗
L1SR_COHORTCited in: Prognosis and Natural History - [66]
Nikolakis G, Kaleta KP, Vaiopoulos AG et al.. “Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review.” Dermatology (Basel, Switzerland) (2020). PMID: 32942279 ↗
L2SR_COHORTCited in: Prognosis and Natural History - [67]
Tanizaki H, Hayashi N, Abe M. “Evaluation of the efficacy of maintenance therapy for acne vulgaris using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel for 24 weeks and assessment of atrophic acne scars using three-dimensional image analysis.” The Journal of dermatology (2023). PMID: 37665181 ↗
L1RCTCited in: Prognosis and Natural History, Prevention, Screening and Surveillance - [68]
Al-Sudany NK, Mohammed NH, Alrifai SB. “Downregulation of S100a7a antimicrobial peptide in acne vulgaris patients after isotretinoin therapy.” Dermatologic therapy (2019). PMID: 31639246 ↗
L1RCTCited in: Prognosis and Natural History - [69]
Pour Mohammad A, Seirafianpour F, Jafarzadeh A et al.. “A comprehensive systematic review on the efficacy, safety, tolerability, and relapse rates of modern procedural therapies for inflammatory and non-inflammatory acne vulgaris.” Lasers in medical science (2025). PMID: 40993442 ↗
L2SR_COHORTCited in: Prognosis and Natural History - [70]
Hasan F, Liaquat A, Raza A et al.. “Effectiveness of upadacitinib in ulcerative colitis patients with prior tofacitinib exposure: a systematic review and meta-analysis.” Annals of gastroenterology (2025). PMID: 40937059 ↗
L2SR_COHORTCited in: Prognosis and Natural History - [71]
Wang L, Wang H, Zhou J et al.. “Long-term impact of antibiotic exposure duration on recurrence and microbial resistance in moderate-to-severe acne: a real-world retrospective analysis.” Frontiers in medicine (2026). PMID: 41994433 ↗
L3RETROSPECTIVE_COHORTCited in: Prognosis and Natural History - [72]
Wang X, Fan MJ, Yu YF et al.. “Acromegaly presented with acne vulgaris: a retrospective study with 123 cases.” Journal of endocrinological investigation (2023). PMID: 38112910 ↗
L4COHORTCited in: Prognosis and Natural History - [73]
Bocquet-Trémoureux S, Corvec S, Khammari A et al.. “Acne fulminans and Cutibacterium acnes phylotypes.” Journal of the European Academy of Dermatology and Venereology : JEADV (2020). PMID: 31715640 ↗
L3COHORTCited in: Prognosis and Natural History - [74]
Chien AL, Tsai J, Leung S et al.. “Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics.” JAMA dermatology (2019). PMID: 30758497 ↗
L2COHORTCited in: Prognosis and Natural History - [75]
Qiu X, Feng Y, Mo X et al.. “Multi-Omics Analysis Identifies Genetic Mechanisms and Therapeutic Targets for Acne Vulgaris.” The Journal of investigative dermatology (2025). PMID: 40398594 ↗
L5OTHERCited in: Prognosis and Natural History - [76]
Jung Y, Tam J, Ray Jalian H et al.. “Longitudinal, 3D in vivo imaging of sebaceous glands by coherent anti-stokes Raman scattering microscopy: normal function and response to cryotherapy.” The Journal of investigative dermatology (2014). PMID: 25026458 ↗
L5OTHERCited in: Prognosis and Natural History - [77]
Poulin Y, Sanchez NP, Bucko A et al.. “A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial.” The British journal of dermatology (2011). PMID: 21457209 ↗
L1RCTCited in: Prevention, Screening and Surveillance - [78]
Thiboutot D, Layton AM, Traore I et al.. “International expert consensus recommendations for the use of dermocosmetics in acne.” Journal of the European Academy of Dermatology and Venereology : JEADV (2024). PMID: 38877766 ↗
L1GUIDELINECited in: Prevention, Screening and Surveillance - [79]
Hayashi N, Akamatsu H, Iwatsuki K et al.. “Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017.” The Journal of dermatology (2018). PMID: 29782039 ↗
L1GUIDELINECited in: Prevention, Screening and Surveillance - [80]
Alexis A, Del Rosso JQ, Forman S et al.. “Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation.” International journal of dermatology (2024). PMID: 38685118 ↗
L1RCTCited in: Prevention, Screening and Surveillance - [81]
Corcoran L, Muller I, Layton AM et al.. “Systematic review of clinical practice guidelines for acne vulgaris published between January 2017 and July 2021.” Skin health and disease (2023). PMID: 37538340 ↗
L5GUIDELINECited in: Prevention, Screening and Surveillance - [82]
Leung AK, Barankin B, Lam JM et al.. “Dermatology: how to manage acne vulgaris.” Drugs in context (2021). PMID: 34691199 ↗
L5RCTCited in: Prevention, Screening and Surveillance - [83]
Nicklas C, Rubio R, Cárdenas C et al.. “Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial.” Photodermatology, photoimmunology & photomedicine (2018). PMID: 29993146 ↗
L1RCTCited in: Prevention, Screening and Surveillance - [84]
Kircik LH. “Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Aqueous Gel: Long-Term Use in Adult Females With Moderate Acne Vulgaris.” Journal of drugs in dermatology : JDD (2017). PMID: 28686771 ↗
L4RCTCited in: Prevention, Screening and Surveillance - [85]
Kircik LH. “Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment.” Journal of drugs in dermatology : JDD (2016). PMID: 26885787 ↗
L4RCTCited in: Prevention, Screening and Surveillance - [86]
Baumann LS, Oresajo C, Yatskayer M et al.. “Comparison of clindamycin 1% and benzoyl peroxide 5% gel to a novel composition containing salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, and dioic acid in the treatment of acne vulgaris.” Journal of drugs in dermatology : JDD (2013). PMID: 23545907 ↗
L1RCTCited in: Prevention, Screening and Surveillance - [87]
Kircik LH, Dahl A, Yatskayer M et al.. “Safety and efficacy of two anti-acne/anti-aging treatments in subjects with photodamaged skin and mild to moderate acne vulgaris.” Journal of drugs in dermatology : JDD (2012). PMID: 22648221 ↗
L1RCTCited in: Prevention, Screening and Surveillance - [88]
Alirezai M, George SA, Coutts I et al.. “Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline.” European journal of dermatology : EJD (2007). PMID: 17324827 ↗
L1RCTCited in: Prevention, Screening and Surveillance - [89]
Samuels DV, Rosenthal R, Lin R et al.. “Acne vulgaris and risk of depression and anxiety: A meta-analytic review.” Journal of the American Academy of Dermatology (2020). PMID: 32088269 ↗
L1SR_COHORTCited in: Prevention, Screening and Surveillance - [90]
Zhou R, Jiang X. “Effects of adapalene-benzoyl peroxide combination gel in treatment or maintenance therapy of moderate or severe acne vulgaris: a meta-analysis.” Annals of dermatology (2014). PMID: 24648685 ↗
L1SR_COHORTCited in: Prevention, Screening and Surveillance - [91]
Bree AF, Siegfried EC. “Acne vulgaris in preadolescent children: recommendations for evaluation.” Pediatric dermatology (2013). PMID: 24274782 ↗
L4RETROSPECTIVE_COHORTCited in: Prevention, Screening and Surveillance - [92]
Sun X, Qian F, He Y et al.. “Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study.” Advances in therapy (2020). PMID: 31950432 ↗
L4NON_RANDOMIZED_TRIALCited in: Prevention, Screening and Surveillance